CA2841313A1 - Nouveaux reactifs de reticulation, nouvelles macromolecules, nouveaux conjugues therapeutiques, et procedes de synthese associes - Google Patents
Nouveaux reactifs de reticulation, nouvelles macromolecules, nouveaux conjugues therapeutiques, et procedes de synthese associes Download PDFInfo
- Publication number
- CA2841313A1 CA2841313A1 CA2841313A CA2841313A CA2841313A1 CA 2841313 A1 CA2841313 A1 CA 2841313A1 CA 2841313 A CA2841313 A CA 2841313A CA 2841313 A CA2841313 A CA 2841313A CA 2841313 A1 CA2841313 A1 CA 2841313A1
- Authority
- CA
- Canada
- Prior art keywords
- group
- compound
- independently selected
- alkyl
- pyridyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C291/00—Compounds containing carbon and nitrogen and having functional groups not covered by groups C07C201/00 - C07C281/00
- C07C291/02—Compounds containing carbon and nitrogen and having functional groups not covered by groups C07C201/00 - C07C281/00 containing nitrogen-oxide bonds
- C07C291/04—Compounds containing carbon and nitrogen and having functional groups not covered by groups C07C201/00 - C07C281/00 containing nitrogen-oxide bonds containing amino-oxide bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/44—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
- C07D207/444—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5
- C07D207/448—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. maleimide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/70—Sulfur atoms
- C07D213/71—Sulfur atoms to which a second hetero atom is attached
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D229/00—Heterocyclic compounds containing rings of less than five members having two nitrogen atoms as the only ring hetero atoms
- C07D229/02—Heterocyclic compounds containing rings of less than five members having two nitrogen atoms as the only ring hetero atoms containing three-membered rings
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Neurosurgery (AREA)
- Polymers & Plastics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Peptides Or Proteins (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Polyethers (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
Abstract
La présente invention concerne de nouvelles entités chimiques à base de polyols. Ces nouvelles entités chimiques sont biocompatibles et biodégradables. Les molécules peuvent être faites sous une forme simple et pure. Ces molécules peuvent avoir une masse moléculaire dans la plage d'une petite masse moléculaire (< 1000 Da) à une grande masse moléculaire (1000 à 120 000 Da). Les molécules à base de polyol peuvent avoir des groupes fonctionnels dans toute la molécule pour la réticulation de composés, par exemple pour la préparation de conjugués anticorps-médicament, ou pour faciliter la délivrance de protéines thérapeutiques, de peptides, d'ARNsi, et de médicaments chimiothérapeutiques. La présente invention concerne en outre de nouvelles entités de conjugués préparées avec lesdites molécules à base de polyol. La présente invention concerne également la synthèse de molécules à base de polyol et de conjugués.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161509296P | 2011-07-19 | 2011-07-19 | |
US61/509,296 | 2011-07-19 | ||
PCT/US2012/047255 WO2013012961A2 (fr) | 2011-07-19 | 2012-07-18 | Nouveaux réactifs de réticulation, nouvelles macromolécules, nouveaux conjugués thérapeutiques, et procédés de synthèse associés |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2841313A1 true CA2841313A1 (fr) | 2013-01-24 |
CA2841313C CA2841313C (fr) | 2023-10-24 |
Family
ID=46640108
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2841313A Active CA2841313C (fr) | 2011-07-19 | 2012-07-18 | Nouveaux reactifs de reticulation, nouvelles macromolecules, nouveaux conjugues therapeutiques, et procedes de synthese associes |
Country Status (8)
Country | Link |
---|---|
US (1) | US8907079B2 (fr) |
EP (1) | EP2734238B1 (fr) |
JP (1) | JP6240599B2 (fr) |
CN (2) | CN107043339B (fr) |
AU (1) | AU2012284055B2 (fr) |
BR (1) | BR112014000324A8 (fr) |
CA (1) | CA2841313C (fr) |
WO (1) | WO2013012961A2 (fr) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9511150B2 (en) | 2011-07-19 | 2016-12-06 | CellMosaic, Inc. | Crosslinking reagents, macromolecules, therapeutic bioconjugates, and synthetic methods thereof |
JP6762094B2 (ja) * | 2013-02-28 | 2020-09-30 | タフツ ユニバーシティー | 薬剤のデリバリーのためのジスルフィド化合物 |
ES2759503T3 (es) | 2013-05-02 | 2020-05-11 | Glykos Finland Oy | Conjugados de una glicoproteína o un glicano con una carga útil tóxica |
ES2779974T3 (es) | 2014-06-13 | 2020-08-21 | Tenboron Oy | Conjugados que comprenden un anticuerpo anti-egfr1 |
EP3160513B1 (fr) | 2014-06-30 | 2020-02-12 | Glykos Finland Oy | Dérivé de saccharide d'une charge utile toxique et conjugués d'anticorps de celui-ci |
TWI648271B (zh) * | 2014-09-23 | 2019-01-21 | 日商住友電木股份有限公司 | 二氮環丙烯化合物及由其衍生之組成物 |
CN104560026A (zh) * | 2014-12-25 | 2015-04-29 | 温州医科大学附属第二医院 | 一种活体卵巢癌组织的靶向muc1的荧光探针及其制备方法 |
CN108135182A (zh) * | 2015-10-05 | 2018-06-08 | 先正达参股股份有限公司 | 保存核糖核酸生物活性的方法 |
JP6412906B2 (ja) * | 2015-11-03 | 2018-10-24 | 財團法人工業技術研究院Industrial Technology Research Institute | 化合物、リンカー−薬物およびリガンド−薬物複合体 |
EP3678701A4 (fr) | 2017-09-05 | 2021-12-01 | Torque Therapeutics, Inc. | Compositions protéiques thérapeutiques et procédés de préparation et d'utilisation de celles-ci |
KR20210031848A (ko) | 2017-09-05 | 2021-03-23 | 토크 테라퓨틱스, 인코포레이티드 | 가역적 링커 및 이의 용도 |
US20210170037A1 (en) * | 2018-05-01 | 2021-06-10 | Cellmosaic Inc. | Branched sugar alcohol-based compounds, and compositions and methods thereof |
CN109142330B (zh) * | 2018-07-31 | 2020-09-11 | 漯河医学高等专科学校 | ZnS-CeO2-WO3-Al2O3丙酮氰醇气体传感器材料的制备方法及丙酮氰醇气体传感器 |
CN109776625B (zh) * | 2019-03-18 | 2022-08-23 | 南京江原安迪科正电子研究发展有限公司 | 一种d-甘露糖的合成方法 |
WO2020215144A1 (fr) * | 2019-04-26 | 2020-10-29 | Xlynx Materials Inc. | Molécules à base de diazirine et utilisations associées |
CN110563698A (zh) * | 2019-07-25 | 2019-12-13 | 苏州昊帆生物股份有限公司 | 一种新型蛋白质交联剂及其制备方法 |
US20220298399A1 (en) * | 2021-03-19 | 2022-09-22 | Facebook Technologies, Llc | Synthesis and use of multi-functional diazirine adhesives for elastomer bonding |
CN117279664A (zh) | 2021-04-10 | 2023-12-22 | 普方生物制药美国公司 | Folr1结合剂、其偶联物及其使用方法 |
EP4326768A1 (fr) | 2021-04-23 | 2024-02-28 | Profoundbio Us Co. | Anticorps anti-cd70, leurs conjugués et leurs procédés d'utilisation |
TW202320857A (zh) | 2021-07-06 | 2023-06-01 | 美商普方生物製藥美國公司 | 連接子、藥物連接子及其結合物及其使用方法 |
CN115043899A (zh) * | 2022-05-24 | 2022-09-13 | 南开大学 | 双胺或胺与硫醇偶联的化合物及其制备方法和应用 |
CN117835778A (zh) * | 2022-09-26 | 2024-04-05 | 清华大学 | 图案化量子点薄膜的制备方法、光电器件与电子设备 |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2258892A (en) * | 1938-08-25 | 1941-10-14 | Benjamin R Harris | Ethers of polyglycerols |
US2520671A (en) | 1946-10-24 | 1950-08-29 | Gen Mills Inc | Polyhydroxy compounds |
US2532036A (en) | 1946-10-24 | 1950-11-28 | Gen Mills Inc | Process of preparing polyhydric alcohols |
US2520670A (en) | 1946-10-24 | 1950-08-29 | Gen Mills Inc | Polyglycerols |
GB723244A (en) * | 1951-04-10 | 1955-02-02 | Unilever Ltd | Improvements in or relating to surface-active agents |
US4172094A (en) | 1976-12-03 | 1979-10-23 | Merck & Co., Inc. | Polyamine compounds |
DE4124283A1 (de) | 1991-07-15 | 1993-01-21 | Degussa | Umesterung von peptiden |
GB9121279D0 (en) | 1991-10-08 | 1991-11-20 | Cerestar Holding Bv | Process for the production of aminopolyols |
FR2701949B1 (fr) | 1993-02-22 | 1997-01-24 | Picardie Jules Verne Universit | Procédé de synthèse de nouveaux composés disaccharidiques, sans jonction glycosidique, produits obtenus par ce procédé et leurs applications comme médicament tensioactif ou agent chélatant. |
DE69419601T2 (de) | 1993-03-17 | 1999-12-02 | Kao Corp | Aminderivate und sie enthaltende dermatologische zubereitungen |
ES2226881T3 (es) | 1999-07-16 | 2005-04-01 | Imperial Chemical Industries Plc | Composiciones agroquimicas y compuestos surfactantes. |
DE60130743T2 (de) * | 2000-03-24 | 2008-07-17 | Biosphere Medical, Inc., Rockland | Mikrokugeln zur aktiven embolisierung |
MXPA04012496A (es) | 2002-06-21 | 2005-09-12 | Novo Nordisk Healthcare Ag | Glicoformos del factor vii pegilados. |
WO2004025297A1 (fr) | 2002-07-30 | 2004-03-25 | Reverse Proteomics Research Institute Co., Ltd. | Procede pour empecher une interaction non specifique entre des molecules sur un support solide |
FI20021772A (fi) * | 2002-10-04 | 2004-04-05 | Biotie Therapies Oyj | Uudet hiilihydraattikoostumukset ja menetelmä niiden valmistamiseksi |
AU2003273413A1 (en) * | 2002-10-08 | 2004-05-04 | Fresenius Kabi Deutschland Gmbh | Pharmaceutically active oligosaccharide conjugates |
US7560231B2 (en) * | 2002-12-20 | 2009-07-14 | Roche Molecular Systems, Inc. | Mannitol and glucitol derivatives |
US6995245B2 (en) | 2003-05-30 | 2006-02-07 | Centocor, Inc. | Formation of novel erythropoietin conjugates using transglutaminase |
US7842661B2 (en) | 2003-11-24 | 2010-11-30 | Novo Nordisk A/S | Glycopegylated erythropoietin formulations |
CA2549409C (fr) | 2003-12-03 | 2013-10-29 | Neose Technologies, Inc. | Facteur de stimulation de colonies de granulocytes glycopegyle |
WO2005056760A2 (fr) | 2003-12-03 | 2005-06-23 | Neose Technologies, Inc. | Hormone stimulant le follicule humain glycopegyle |
JP2008514215A (ja) * | 2004-09-29 | 2008-05-08 | ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト | 改変タンパク質 |
US20070134243A1 (en) * | 2004-12-01 | 2007-06-14 | Gazzard Lewis J | Antibody drug conjugates and methods |
EP1838332A1 (fr) | 2005-01-06 | 2007-10-03 | Neose Technologies, Inc. | Glycoconjugaison a l'aide de fragments de saccharyl |
WO2006084888A2 (fr) | 2005-02-10 | 2006-08-17 | Novo Nordisk A/S | Hormones de croissance pegylees a leur extremite c |
KR100699279B1 (ko) * | 2005-04-28 | 2007-03-23 | 학교법인 포항공과대학교 | 당 또는 당 유사체를 골격으로 하는 분자 수송체 및 그의제조방법 |
EP4026840A1 (fr) * | 2005-07-18 | 2022-07-13 | Seagen Inc. | Conjugués de médicaments de linker bêta-glucuronide |
PL206420B1 (pl) | 2006-08-03 | 2010-08-31 | Politechnika Wroclawska | Nowe pochodne disorbityloaminy i sposób ich otrzymywania |
ITMI20061624A1 (it) | 2006-08-11 | 2008-02-12 | Bioker Srl | Mono-coniugati sito-specifici di g-csf |
FR2906245A1 (fr) | 2006-09-25 | 2008-03-28 | Oreal | Diamides hydroxyles agent d'hydratation de la peau |
WO2008073463A2 (fr) * | 2006-12-11 | 2008-06-19 | Wyeth | Méthodes et compositions pour le traitement et le contrôle d'un traitement de troubles associés à il-13 |
CN101600456A (zh) * | 2006-12-11 | 2009-12-09 | 惠氏公司 | 治疗il-13相关疾病和监测il-13相关疾病治疗的方法和组合物 |
FR2921838A1 (fr) | 2007-10-05 | 2009-04-10 | Guerbet Sa | Nouveau procede de preparation de nanoparticules recouvertes d'une couche stabilisatrice gem-bisphosphonate couplee a des ligands de biodistribution hydrophile |
JP2009249500A (ja) | 2008-04-07 | 2009-10-29 | Hakuto Co Ltd | 重合性高分岐ポリマー及びその製造方法 |
EP2123304A1 (fr) * | 2008-05-23 | 2009-11-25 | Freie Universität Berlin | Composés utilisés en tant que nanotransporteurs et leur utilisation |
JP2013500237A (ja) | 2008-07-31 | 2013-01-07 | シエル・インターナシヨネイル・リサーチ・マーチヤツピイ・ベー・ウイ | ポリ(ヒドロキシカルボン酸)アミド塩誘導体及びそれを含有する潤滑組成物 |
WO2010080817A2 (fr) * | 2009-01-06 | 2010-07-15 | Utah State University | Conjugués glucide-cyclopamine en tant qu'agents anticancéreux |
WO2010134476A1 (fr) | 2009-05-19 | 2010-11-25 | 日産化学工業株式会社 | Agent gélifiant de type glycyl polyol à longue chaîne et gel |
-
2012
- 2012-07-18 BR BR112014000324A patent/BR112014000324A8/pt not_active Application Discontinuation
- 2012-07-18 CA CA2841313A patent/CA2841313C/fr active Active
- 2012-07-18 CN CN201710164951.6A patent/CN107043339B/zh active Active
- 2012-07-18 CN CN201280034231.3A patent/CN104066451B/zh active Active
- 2012-07-18 EP EP12745599.6A patent/EP2734238B1/fr active Active
- 2012-07-18 AU AU2012284055A patent/AU2012284055B2/en active Active
- 2012-07-18 WO PCT/US2012/047255 patent/WO2013012961A2/fr active Application Filing
- 2012-07-18 JP JP2014521744A patent/JP6240599B2/ja not_active Expired - Fee Related
-
2014
- 2014-03-13 US US14/210,121 patent/US8907079B2/en active Active - Reinstated
Also Published As
Publication number | Publication date |
---|---|
CN104066451B (zh) | 2017-04-05 |
US20140206903A1 (en) | 2014-07-24 |
AU2012284055B2 (en) | 2017-09-07 |
WO2013012961A3 (fr) | 2013-08-01 |
BR112014000324A8 (pt) | 2019-01-29 |
AU2012284055A1 (en) | 2014-01-30 |
JP6240599B2 (ja) | 2017-11-29 |
CN107043339B (zh) | 2019-09-06 |
BR112014000324A2 (pt) | 2017-02-07 |
CN107043339A (zh) | 2017-08-15 |
US8907079B2 (en) | 2014-12-09 |
CA2841313C (fr) | 2023-10-24 |
EP2734238B1 (fr) | 2020-02-19 |
EP2734238A2 (fr) | 2014-05-28 |
CN104066451A (zh) | 2014-09-24 |
JP2014521319A (ja) | 2014-08-28 |
WO2013012961A2 (fr) | 2013-01-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2841313C (fr) | Nouveaux reactifs de reticulation, nouvelles macromolecules, nouveaux conjugues therapeutiques, et procedes de synthese associes | |
US9907854B2 (en) | Crosslinking reagents, macromolecules, therapeutic bioconjugates, and synthetic methods thereof | |
US11850286B2 (en) | Sulfamide linker, conjugates thereof, and methods of preparation | |
US20210170037A1 (en) | Branched sugar alcohol-based compounds, and compositions and methods thereof | |
KR101770584B1 (ko) | 신규 접합체, 그의 제조법, 및 그의 치료 용도 | |
JP2014521319A5 (fr) | ||
JP2018062655A (ja) | 分岐型ヘテロ単分散ポリエチレングリコール、その製造方法、及びその結合体 | |
CA2528667C (fr) | Reactifs pour modifier des agents pharmaceutiques biologiques, leur preparation et leur utilisation | |
US20100160409A1 (en) | Highly Branched Reagents For Modifying Biopharmaceuticals, Their Preparation And Use | |
US20120129919A1 (en) | Polycationic amphiphilic cyclooligosaccharides and the use thereof as molecular transporters | |
EP3166645B1 (fr) | Conjugaison à sélectivité de site d'un conjugué oligonucléotidique à une protéine de liaison de métaux | |
CN116761819A (zh) | 化合物或其盐、以及由它们得到的抗体 | |
CA3203849A1 (fr) | Lieurs d'ester a double clivage pour conjugues anticorps-medicament | |
Paul | Probing receptors and enzymes with synthetic small molecules | |
NZ741734B2 (en) | Novel cryptophycin compounds and conjugates, their preparation and their therapeutic use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request |
Effective date: 20170717 |
|
EEER | Examination request |
Effective date: 20170717 |
|
EEER | Examination request |
Effective date: 20170717 |
|
EEER | Examination request |
Effective date: 20170717 |
|
EEER | Examination request |
Effective date: 20170717 |
|
EEER | Examination request |
Effective date: 20170717 |
|
EEER | Examination request |
Effective date: 20170717 |
|
EEER | Examination request |
Effective date: 20170717 |